-
PARP Protein, Mouse, Recombinant (His Tag)
PARP Protein, Mouse, Recombinant (His Tag)
- 中文名称：
- PARP Protein, Mouse, Recombinant (His Tag)
- 英文名称：
- PARP Protein, Mouse, Recombinant (His Tag)
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA257485
- 规格：
- 0.1 mg|2x0.1 mg|3x0.1 mg|4x0.1 mg|5x0.1 mg
- 保存建议：
- Samples are stable for up to twelve months from date of receipt at -20 degree C to -80 degree C. Store it under sterile conditions at -20 degree C to -80 degree C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Shipping: They are shipped out with blue ice pack
- 货期：
- 6-8周
- 纯度：
- >85 % as determined by SDS-PAGE
- 产品形式：
- Lyophilized from sterile 20mM Tris, 500mM NaCl, pH8.0, 10% gly, 0.1mM TCEP Normally 5%-8% trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 说明书：
Poly (ADP-ribose) polymerase 1(PRAP1), also known as NAD(+) ADP-ribosyltransferase 1(ADPRT), is a chromatin-associated enzyme that modifies various nuclear proteins by poly(ADP-ribosyl)ation. The ADP-D-ribosyl group of NAD+ is transferred to an acceptor carboxyl group on a histone or the enzyme itself, and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 2-3 units. The poly(ADP-ribosyl)ation modification is critical for a wide range of processes, including DNA repair, regulation of chromosome structure, transcriptional regulation, mitosis and apoptosis. PARP1 is demonstrated to mediate the poly(ADP-ribose) ation of APLF (aprataxin PNK-like factor) and CHFR (checkpoint protein with FHA and RING domains), two representative proteins involved in the DNA damage response and checkpoint regulation. Further, It has been suggested that DNA-dependent protein kinase (DNA-PK), another component of DNA repair, suppresses PARP activity, probably through direct binding and/or sequestration of DNA-ends which serve as an important stimulator for both enzymes. PARP1 inhibitors are thus proposed as a targeted cancer therapy for recombination deficient cancers, such as BRCA2 tumors.
